ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$33.6

Market cap

$3.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$3.54B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The quick ratio has soared by 118% YoY and by 42% from the previous quarter
The equity has grown by 18% from the previous quarter
The net income has declined by 34% year-on-year but it has increased by 2.8% since the previous quarter
ARWR's EPS is down by 31% YoY but it is up by 2.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
106.9M
Market cap
$3.59B
Enterprise value
$3.54B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.15
Price to sales (P/S)
13.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.98
Earnings
Revenue
$272.8M
EBIT
-$144M
EBITDA
-$133.39M
Free cash flow
-$353.17M
Per share
EPS
-$1.42
Free cash flow per share
-$3.31
Book value per share
$4.12
Revenue per share
$2.56
TBVPS
$8.24
Balance sheet
Total assets
$891.31M
Total liabilities
$426.2M
Debt
$82.78M
Equity
$446.77M
Working capital
$487.66M
Liquidity
Debt to equity
0.19
Current ratio
6.6
Quick ratio
6.32
Net debt/EBITDA
0.39
Margins
EBITDA margin
-48.9%
Gross margin
100%
Net margin
-55.1%
Operating margin
-55.2%
Efficiency
Return on assets
-18.6%
Return on equity
-35.8%
Return on invested capital
-23.5%
Return on capital employed
-17.9%
Return on sales
-52.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
0.09%
1 week
-7.36%
1 month
-5.41%
1 year
0.81%
YTD
-17.16%
QTD
32.28%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$272.8M
Gross profit
$272.8M
Operating income
-$150.71M
Net income
-$150.21M
Gross margin
100%
Net margin
-55.1%
The net income has declined by 34% year-on-year but it has increased by 2.8% since the previous quarter
Arrowhead Pharmaceuticals's net margin has decreased by 30% YoY
The operating income has declined by 27% year-on-year but it rose by 4.2% since the previous quarter
The operating margin has declined by 23% year-on-year but it has increased by 2.3% since the previous quarter

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.15
P/S
13.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.98
ARWR's EPS is down by 31% YoY but it is up by 2.7% from the previous quarter
The price to book (P/B) is 31% lower than the 5-year quarterly average of 11.8 and 5% lower than the last 4 quarters average of 8.6
The equity has grown by 18% from the previous quarter
The price to sales (P/S) is 68% less than the 5-year quarterly average of 41.5 and 4% less than the last 4 quarters average of 13.7
The company's revenue rose by 3.6% YoY

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
The company's return on equity fell by 34% YoY but it rose by 2.7% QoQ
Arrowhead Pharmaceuticals's return on invested capital has increased by 22% YoY and by 16% QoQ
ARWR's ROS is down by 21% YoY but it is up by 4.2% from the previous quarter
The company's return on assets fell by 16% YoY but it rose by 8% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 109% higher than its total liabilities
The company's current ratio has surged by 119% YoY and by 40% QoQ
The quick ratio has soared by 118% YoY and by 42% from the previous quarter
Arrowhead Pharmaceuticals's debt is 81% lower than its equity
The equity has grown by 18% from the previous quarter
The debt to equity has contracted by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.